Core Viewpoint - The company has passed the Hong Kong Stock Exchange listing hearing and is in the commercialization stage of its pharmaceutical business, with a focus on both generic and innovative drug development [1] Company Overview - The company is a commercial-stage pharmaceutical enterprise with capabilities in research and development, production, and sales [1] - It has received approval for 14 generic drugs and has four innovative drugs in the pipeline [1] Product Portfolio - The company's commercial product portfolio includes generic drugs targeting the digestive system, cardiovascular system, endocrine system, nervous system, and inflammatory diseases [1] - Four generic drugs are included in the National Volume-Based Procurement (VBP) program, contributing significantly to revenue [1] Revenue Contribution - In 2024, products such as Anbili, Haihuitong, Ruiantuo, and Saixifu are expected to contribute significantly to the company's revenue, with Haihuitong holding the largest market share in China [1]
海西新药通过港交所聆讯 华泰国际和招银国际为联席保荐人
Zheng Quan Shi Bao Wang·2025-09-30 00:19